Inhibition of SARS-CoV-2 3CL protease by the anti-viral chimeric protein RetroMAD1

COVID-19 results from SARS-CoV-2, which mutates frequently, challenging current treatments. Therefore, it is critical to develop new therapeutic drugs against this disease. This study explores the interaction between SARS-CoV-2 3CL(pro) and RetroMAD1, a well-characterized coronavirus protein and pot...

Descripción completa

Detalles Bibliográficos
Autores principales: Chan, Lee-Chin, Mat Yassim, Aini Syahida, Ahmad Fuaad, Abdullah Al Hadi, Leow, Thean Chor, Sabri, Suriana, Radin Yahaya, Radin Shafierul, Abu Bakar, Awang Muhammad Sagaf
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10656507/
https://www.ncbi.nlm.nih.gov/pubmed/37978223
http://dx.doi.org/10.1038/s41598-023-47511-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10656507/
https://www.ncbi.nlm.nih.gov/pubmed/37978223
http://dx.doi.org/10.1038/s41598-023-47511-z

Ejemplares similares